CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
Ofatumumab +2 moredrug
Likely dose
Ofatumumab 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01555541
NCT01555541Phase 2Completed
CompareCT.gov

A Phase II Study of Intensive Consolidation and Stem Cell Mobilization Therapy With Ofatumumab, Etoposide, and High-dose Ara-C (OVA), Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

C. Babis Andreadis·interventional·Posted Mar 15, 2012·Updated Jun 29, 2022

In Brief

A Phase 2 clinical trial evaluating Ofatumumab, Etoposide, and 1 other intervention for Diffuse Large Cell Lymphoma Relapsed/Refractory. Completed, enrolled 19 participants across 1 site.

Detailed Summary

The goal of this clinical trial is to show that incorporating ofatumumab instead of rituximab in combination with etoposide and cytarabine (OVA) is successful in collecting autologous stem cells for use in an autologous stem cell transplantation (autoSCT) and to examine its effectiveness in eliminating residual diffuse large B-Cell Lymphoma (DLBCL) in patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large Cell Lymphoma Relapsed/Refractory
CountriesUnited States
CollaboratorsUniversity of California, San Francisco, GlaxoSmithKline

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 15, 2012
Enrollment StartMay 25, 2012
Primary CompletionJul 6, 2017
Study CompletionJul 1, 2021
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 14.3 years ago

Interventions

Ofatumumabdrug

1000 mg IV days 0, 7, 14, 21

Etoposidedrug

10 mg/Kg IV over 24 hours daily, days 1-4

Cytarabinedrug

2000 mg/m2 IV twice daily, days 1-4